Which GLP-1 Has the Fewest Side Effects? (2026)

See if you qualify — start your visit →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: full refund if you're not satisfied in your first 30 days (3-month and 6-month plans)

At a glance: GLP-1 side-effect comparison

All figures are from clinical trials of FDA-approved branded medications and are population averages, not individual outcomes. Individual results vary. Sources: Wegovy® and Zepbound® FDA prescribing information; STEP-1 (Wilding et al., NEJM 2021); SURMOUNT-1 (Jastreboff et al., NEJM 2022).

Why both GLP-1 medications share the same side-effect profile

Semaglutide is a GLP-1 receptor agonist — it activates the glucagon-like peptide-1 receptor, which slows gastric emptying, reduces appetite, and acts on the brain's appetite centers. Because the GI tract is rich in GLP-1 receptors, slowing gastric motility reliably produces nausea, particularly when a dose is first increased.

Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. That second mechanism may partly offset GLP-1-driven nausea, which is one proposed explanation for why tirzepatide's label nausea rate is lower. But both drugs delay gastric emptying, so the GI side-effect class is identical: nausea, vomiting, diarrhea, constipation, and abdominal discomfort — always worst after a dose increase.

The practical implication: choosing between these drugs primarily to avoid side effects is unlikely to produce a dramatically different experience. The larger lever is how slowly the dose is escalated.

Semaglutide's side-effect profile: what the STEP-1 trial showed

The STEP-1 trial — the pivotal phase 3 study of semaglutide 2.4 mg (Wegovy®) for obesity — enrolled 1,961 adults and is the primary source of side-effect data on the prescribing label. The trial data showed: Wilding et al., NEJM 2021.

• Nausea: ~44% of participants in the semaglutide group reported nausea, versus ~15.8% with placebo.
• Vomiting: ~24.5% versus ~6.8% with placebo.
• Diarrhea: ~29.7% versus ~15.9% with placebo.
• Constipation: ~24.2% versus ~11.0% with placebo.
• Discontinuation due to GI adverse events: ~4.5% in the semaglutide group.

The large majority of GI events were mild or moderate in severity and occurred primarily in the titration phase — when the dose was being increased every four weeks. By the time participants reached their maintenance dose, GI symptoms had substantially decreased for most.

These data are from the STEP-1 trial of Wegovy® (semaglutide 2.4 mg), an FDA-approved branded medication. They do not describe the effects of compounded semaglutide, which has not been studied in these trials.

Tirzepatide's side-effect profile: what SURMOUNT-1 showed

The SURMOUNT-1 trial — the pivotal phase 3 study of tirzepatide (Zepbound®/Mounjaro®) for obesity — enrolled 2,539 adults across three dose arms. Side-effect data from this trial inform the prescribing label. Source: Jastreboff et al., NEJM 2022.

• Nausea: ~28–33% (range across 5 mg, 10 mg, and 15 mg doses) versus ~10% with placebo.
• Vomiting: ~8–10% across doses versus ~2.3% with placebo.
• Diarrhea: ~17–23% across doses versus ~11% with placebo.
• Constipation: ~11% across doses versus ~5% with placebo.
• Discontinuation due to GI adverse events: ~4–6% across dose groups.

As with semaglutide, the large majority of GI events were mild to moderate and most pronounced during dose-escalation weeks. A slower titration schedule — which tirzepatide trials used — may also partly explain the lower discontinuation rate.

These data are from the SURMOUNT-1 trial of Zepbound®/Mounjaro® (tirzepatide), FDA-approved branded medications. They do not describe the effects of compounded tirzepatide, which has not been studied in these trials.

The head-to-head data: what SURMOUNT-5 showed

The SURMOUNT-5 trial was the first head-to-head study comparing tirzepatide directly to semaglutide for weight loss — both at the highest approved doses (tirzepatide 15 mg vs semaglutide 2.4 mg). The trial was published in NEJM in 2025 and is the best available direct comparison. Source: SURMOUNT-5, NEJM 2025.

On the GI tolerability question, SURMOUNT-5 found that fewer participants in the tirzepatide arm discontinued the study due to GI adverse events compared to the semaglutide arm — consistent with the lower label nausea rate. However, the overall rates of any GI event (across all types: nausea, vomiting, diarrhea, constipation) were broadly similar between the two drugs. The main nausea difference between the labels is better supported than an overall GI advantage.

A 2025 pooled analysis in Diabetes, Obesity and Metabolism reached a similar conclusion: when looking at all GI symptom types together rather than nausea alone, the picture is less clear-cut. GI tolerability pooled analysis, DOM 2025.

The takeaway from the head-to-head data: tirzepatide has a lower-nausea label profile, and fewer people stopped it for GI reasons. But the overall GI burden — when all GI symptoms are considered together — is not dramatically different. Tolerability is highly individual.

Which GLP-1 has the fewest side effects: why there is no clean winner

Nausea favors tirzepatide on the labels. GI-related discontinuations also favor tirzepatide in SURMOUNT-5. But:

• Pooled analyses across all GI symptom types do not show a consistent overall advantage.
• Vomiting rates are lower with tirzepatide; constipation rates are also lower. But diarrhea rates in tirzepatide trials are meaningful, and individuals vary in which GI symptom they find most difficult.
• Titration speed matters: tirzepatide clinical trials used a slower titration schedule than some early semaglutide studies, which may account for some of the tolerability difference independent of the drug itself.
• Older GLP-1 medications (dulaglutide, liraglutide at lower weight-loss doses) may carry milder GI profiles at the cost of less efficacy — though they are less commonly used for weight loss now.

The drug that is gentlest for your neighbor may not be the same for you. For most people, how slowly you titrate matters more than which drug you choose.

Beyond GI effects: the full side-effect picture

GI symptoms get the most attention, but both drugs carry a broader safety profile that applies regardless of which you choose.

Class boxed warning: thyroid C-cell tumors

Both semaglutide and tirzepatide carry a boxed warning — the FDA's most serious warning — for thyroid C-cell tumors, based on animal data. These drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2). Human relevance has not been established, but the contraindication stands. This warning applies equally to both drugs and is not a factor in choosing between them. See: FDA drug guidance resources.

Pancreatitis

Acute pancreatitis has been reported with GLP-1 receptor agonists as a class, including both semaglutide and tirzepatide. Patients with a history of pancreatitis may not be appropriate candidates. Any sustained, severe abdominal pain that may radiate to the back should prompt immediate evaluation.

Gallbladder disease

Both drugs are associated with gallbladder disease, including cholelithiasis (gallstones) and cholecystitis. In the STEP-1 trial, gallbladder-related events occurred in ~2.5% of semaglutide participants versus ~1.2% with placebo. Rapid weight loss — from any cause — is itself a known risk factor for gallstones, so some of this risk may be attributable to weight change rather than the drug mechanism alone.

Cardiovascular considerations

The SELECT trial — a large outcomes trial of semaglutide 2.4 mg in adults with cardiovascular disease and obesity — demonstrated a significant reduction in major adverse cardiovascular events. Source: Lincoff et al., NEJM 2023. This adds an important dimension to the side-effect conversation: for certain patients, semaglutide's cardiovascular benefit may outweigh tolerability differences. Similar outcomes data for tirzepatide are anticipated. A licensed clinician should weigh these factors for each individual.

Heart rate

Both drugs can modestly increase resting heart rate (typically 2–4 bpm on average in trials). For most people this is clinically insignificant, but it may warrant monitoring in people with pre-existing cardiac conditions.

Injection site reactions

Injection site reactions (bruising, redness, swelling) are reported with both drugs but are generally mild and self-limiting. Rotating injection sites helps reduce their frequency.

Pregnancy

Both semaglutide and tirzepatide are contraindicated during pregnancy. Women of childbearing age should discuss contraception with their clinician before starting either medication.

What actually reduces GLP-1 side effects

The titration schedule — how slowly the dose is increased — is the single highest-leverage variable in determining how tolerable a GLP-1 will be. Drug choice is secondary.

• Start at the lowest available dose: both drugs are approved with a stepwise escalation. Skipping early steps to reach an effective dose faster reliably worsens side effects.
• Extend titration intervals if needed: standard schedules increase the dose every four weeks. Spending additional weeks at a lower dose is a common and effective clinical adjustment that does not compromise long-term outcomes.
• Eat smaller, blander meals around dose-change days: high-fat, spicy, or very large meals worsen GI symptoms because gastric emptying is already slowed. Simple starches, small portions, and staying upright after eating help.
• Stay hydrated: nausea can depress fluid intake; consistent hydration helps reduce both nausea and constipation.
• Don't rush dose increases to accelerate results: most of the weight-loss benefit accrues at doses the body has adjusted to, not at the maximum dose. Patience with titration pays off.
• Access ongoing clinical support: a licensed clinician who can review your symptom pattern, slow your titration, or suggest anti-nausea strategies is a meaningful part of managing side effects — not just the starting prescription.

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) also advises that GLP-1 medications be used as part of a comprehensive program that includes dietary and behavioral support — not as standalone treatment — which aligns with the emphasis on ongoing management.

How long do GLP-1 side effects last?

For most people, GI side effects follow a predictable pattern. They are most intense in the first one to four weeks after a dose increase and then diminish substantially as the GI tract adjusts. By the time the dose has been stable for four to six weeks, symptoms are typically much milder or absent.

The critical implication: side effects are mostly a transient titration problem, not a permanent feature of being on the drug. The trial data bear this out — in both STEP-1 and SURMOUNT-1, GI adverse events were front-loaded in the titration phase and largely resolved at maintenance dose.

If side effects persist at a stable dose without improvement after several weeks, that is a signal to discuss dose adjustment or a clinical review, not necessarily a reason to stop treatment entirely.

The serious warnings apply to both drugs equally

Nothing in the tolerability data should obscure the serious class-wide warnings that apply regardless of which GLP-1 is prescribed:

• Boxed warning: thyroid C-cell tumors (contraindicated in personal or family history of MTC or MEN 2).
• Pancreatitis risk — seek immediate care for severe, persistent abdominal pain.
• Gallbladder disease — discuss your history with your clinician before starting.
• Not for use in pregnancy.
• Hypoglycemia risk if used with insulin or sulfonylureas.

A licensed clinician should review your personal and family history against these contraindications before prescribing any GLP-1 medication.

Related comparisons in this series

• Tirzepatide vs. Semaglutide: full clinical comparison
• Which GLP-1 is most effective for weight loss?
• GLP-1 medication costs in 2026: the complete guide
• Brand-name vs. compounded GLP-1: what's the difference?

Where Nouri fits

If you and a licensed clinician decide a GLP-1 is appropriate for you, Nouri offers compounded semaglutide and compounded tirzepatide as part of one complete program — The Program includes clinician-guided GLP-1 therapy (when prescribed), a personalized nutrition plan, a movement plan, and ongoing care support, at one all-inclusive price. Any dose, same price. Longer commitments lower the monthly cost.

Pricing as of June 2026: compounded semaglutide from $120/month on the 6-month plan ($720 billed every 6 months), $145/month on the 3-month plan ($435 billed every 3 months), or $175/month billed monthly. Compounded tirzepatide from $175/month on the 6-month plan ($1,050 billed every 6 months), $199/month on the 3-month plan ($597 billed every 3 months), or $225/month billed monthly. See current pricing at joinnouri.com/becoming. For a broader look at GLP-1 costs across all options, see our 2026 GLP-1 cost guide.

Medication is prepared by Jungle Jim's Pharmacy (Fairfield, OH) and VialsRX — state-licensed 503A compounding pharmacies — and ships free and discreetly to all 50 states.

Nouri is LegitScript-certified. Compounded semaglutide and compounded tirzepatide are patient-specific medications prescribed only when clinically appropriate after a licensed provider reviews your intake. They are not FDA-approved and are not the same as — or therapeutically equivalent to — Wegovy®, Ozempic®, Zepbound®, or Mounjaro®.

The ongoing clinician relationship built into The Program is particularly relevant to the side-effect question: titration can be adjusted, symptoms discussed, and plans modified — all included.

Start your visit with Nouri →
5-minute questionnaire · reviewed by a licensed clinician · The Nouri Promise: if you're not satisfied in your first 30 days, you get a full refund — available on 3-month and 6-month plans · cancel anytime

Frequently asked questions

Which GLP-1 has the least nausea?

On the FDA labels, tirzepatide (Zepbound®/Mounjaro®) has a lower reported nausea rate (~24–33% across doses) than semaglutide at the weight-loss dose used in STEP-1 (~44%). Fewer participants also discontinued tirzepatide for GI reasons in the SURMOUNT-5 head-to-head trial. However, nausea is highly individual, and slow dose titration reduces it more reliably than the choice of drug. These figures come from trials of the FDA-approved branded medications; individual results vary. Compounded versions of these drugs have not been studied in these trials.

Does Ozempic or Mounjaro cause more nausea?

By label rates, Ozempic® (semaglutide, typically prescribed at 1 mg for diabetes) reports nausea in roughly 15–20% of participants at its diabetes dose, while Mounjaro® (tirzepatide) reports nausea at comparable or lower rates at its diabetes doses. The difference is more pronounced at the higher doses used for obesity (Wegovy® ~44%; Zepbound® ~24–33%). Individual tolerance varies considerably, and gradual titration is the biggest single factor in limiting nausea.

Which GLP-1 is easiest on the stomach?

There is no definitive answer. Tirzepatide's label nausea rate is lower than semaglutide's, and fewer participants stopped tirzepatide for GI reasons in SURMOUNT-5 — but pooled analyses across all GI symptom types do not show a consistent overall advantage for either drug. Slow titration is the most controllable lever. Individual tolerance is highly variable and is the strongest predictor of how well any GLP-1 is tolerated.

How long do GLP-1 side effects last?

Most GI side effects are worst in the first one to four weeks after a dose increase and ease substantially as the body adjusts — usually within a few weeks of reaching a stable dose. They are typically mild to moderate in severity. A licensed clinician can slow the titration schedule if symptoms are difficult to manage, or suggest dietary adjustments to reduce GI discomfort.

How can I reduce GLP-1 side effects?

Start at the lowest available dose and increase slowly on the prescribed schedule. Eat smaller, blander meals — particularly on dose-change days. Stay well hydrated. Avoid high-fat, spicy, or very large meals. Do not rush dose escalation. Ongoing support from a licensed clinician to adjust your titration is also important and can make a meaningful difference.

Are there GLP-1 side effects beyond nausea?

Yes. The whole class carries a boxed FDA warning for thyroid C-cell tumors and is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Other class-wide risks include pancreatitis, gallbladder disease, injection-site reactions, modest heart rate increase, and fatigue. These medications are not for use in pregnancy. A licensed clinician should review your medical history against all contraindications before prescribing any GLP-1.

Sources & references

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021. — Tier 1
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022. — Tier 1
3. SURMOUNT-5: Tirzepatide vs Semaglutide head-to-head. NEJM 2025. — Tier 1
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT). NEJM 2023. — Tier 1
5. Wegovy® (semaglutide injection 2.4 mg) FDA prescribing information, 2026. — Tier 1
6. Zepbound® (tirzepatide injection) FDA prescribing information, 2024. — Tier 1
7. GI tolerability pooled analysis. Diabetes, Obesity and Metabolism 2025. — Tier 2
8. NIDDK. Prescription Medications to Treat Overweight and Obesity. National Institutes of Health. — Tier 1 (.gov)
9. FDA. Postmarket Drug Safety Information — GLP-1 Receptor Agonists. — Tier 1

Medically reviewed by Amber Patel, MD · Last reviewed June 29, 2026. Nouri content is reviewed by a licensed clinician and updated as guidance changes. Author: Nouri Editorial Team.

This article is general health education, not medical advice — speak with a licensed clinician about what is right for you. Ozempic®, Wegovy®, and Rybelsus® (semaglutide) are registered trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® (tirzepatide) are registered trademarks of Eli Lilly and Company. Nouri is not affiliated with, endorsed by, or sponsored by these companies. Clinical-trial results described in this article are from studies of the FDA-approved branded medications; compounded semaglutide and compounded tirzepatide have not been studied in these trials, are not FDA-approved, and are not the same as — or therapeutically equivalent to — the brand-name drugs. Compounded semaglutide and compounded tirzepatide are patient-specific medications prescribed only when clinically appropriate after review by a licensed provider. GLP-1 medications carry a boxed FDA warning for thyroid C-cell tumors and are contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2); other risks include pancreatitis, gallbladder disease, and increased heart rate; and they are not for use in pregnancy. Individual results vary. Prices are as of June 2026 and subject to change.